banniere

Information pour les patients / Bibliographie

Bibliographie

POUR LES PATIENTS

  • http://www.heart.org/HEARTORG/Conditions/Arrhythmia/AboutArrhythmia/Atrial-Fibrillation_UCM_302027_Article.jsp6. Atrial fibrillation. Heart and stroke foundation of Québec. http://www.heartandstroke.qc.ca/ access 15 July, .2010 

  • Shea, J. A Patient’s Guide to Living with Atrial Fibrillation. Circulation. 2008; 117e340-e343. Available at http://circ.ahajournals.org/cgi/content/full/117/20/e340. Last accessed July13, 2010.

  • http://www.heartandstroke.com/site/c.ikIQLcMWJtE/b.5052135/k.2C86/Heart_disease__Atrial_fibrillation.htm Heart Rhythm Society. Atrial fibrillation. http://www.hrspatients.org/heart_disorders/atrial_fibrillation/default.asp.

POUR LES PROFESSIONELS

  • Skanes AC, Healy JS, Cairns JA, et al. Society guidelines Focused 202 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines:  Recommendations for Stroke Prevention and Rate/Rhythm Control.  Canadian Journal of Cardiology 2012;20:125-36.

  • Wann LS, Curtis AB, Ellenbogen KA, Estes NAM 3rd, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, writing on behalf of the 2006 ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation Writing Committee. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;123:Epub Feb 15,2011. 

  • Wann LS, Curtis AB, Ellenbogen KA, Estes NAM 3rd, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, writing on behalf of the 2006 ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation Writing Committee. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;123:104-123.

  • European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology. Eur Heart J 2010;31:2369-429..

  • Gillis AM, Skanes AC.  Comparing the 2010 North American and European Atrial Fibrillation Guidelines.  Canadian Journal of Cardiology 2011;27(1):7-9.

  • Healey JS, Parhash R, Pollak T, Tsang T, Dorian P.  Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010:  Etiology and Initial Investigation  Canadian Journal of Cardiology 2011; 27(1):31-7. 

  • Gillis AM, Verma A, Talajic M, Nattel S, Dorian P, CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Rate and Rhythm Management. Canadian Journal of Cardiology 2011; 27: 47-59.

  • Verma A, Macle L, Cox J, Skane AC.  Canadian Society of Cardiology Atrial Fibrillation  2010 - Guidelines on catheter ablation for atrial fibrillation and atrial flutter.  Canadian Journal of Cardiology 2011; 27(1):60-6.

  • Cairns JA, Connolly S, McMurtry S, Stephenson M, Talajic M and the CCCS Atrial Fibrillation Guidelines Committee.  Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010:  Prevention of stroke and systemic thromboemolism in atrial fibrillation and flutter. Canadian J of Cardiology 2011;27: 74-90.

  • Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010 Feb;137(2):263-72. Epub 2009 Sep 17.

  • Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey. Chest. 2010 Nov;138(5):1093-100. 

  • Dabigatran – Product Monograph Canada – Revised Oct 26, 2010.

  • Israel CW, Gronefeld G, Ehrlich JR, Li YG, Hohnloser SH. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. J Am Coll Cardiol 2004 Jan 7; 43(1):47-52.

  • The Stroke Prevention in Atrial Fibrillation, Investigators Committee on Echocardiography. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. Ann Intern Med 1998 Apr 15; 128(8):639-47.

  • Zabalgoitia M, Halperin JL, Pearce LA, Blackshear JL, Asinger RW, Hart RG. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation (III). J Am Coll Cardiol 1998 Jun; 31(7):1622-6.

  • Ezekowitz MD, Reilly PA, Nehmiz G, et al, “Dabigatran With or Without Concomitant Aspirin Compared with Warfarin Alone in Patients With Nonvalvular Atrial Fibrillation (PETRO Study),” Am J Cardiol, 2007, 100(9):1419-26. [PubMed 17950801] 

  • Blech S, Ebner T, Ludwig-Schwellinger E, et al, “The Metabolism and Disposition of The Oral Direct Thrombin Inhibitor, Dabigatran, in Humans,” Drug Metab Dispos, 2008, 36(2):386-99. [PubMed 18006647] 

  • Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007; 167:1414-9.

  • Jonas DE, Bryant Shilliday B, Laundon WR, Pignone M. Patient time requirements of anticoagulation therapy with warfarin. Med Decis Making, 2009, [PubMed 19773584]

  • Luderitz B. & Jung W. (2000) Quality of life in patients with atrial fibrillation. Archives of Internal Medicine 160, 1749–1757.

  • Van Gelder IC, Groenveld HF, Crijns HJ, et al. Rate Control Efficacy in Permanent Atrial Fibrillation: A Comparison Between Lenient Versus Strict Rate Control in Patients With and Without Heart Failure: The RACE II Study, JACC 2010; 55:

  • Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001 Jun 13; 285(22):2864-70. 

  • Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?. JAMA. 2003 Nov 26; 290(20):2685-92.

  • Stangier J, Eriksson BI, Dahl OE, et al, “Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement,” J Clin Pharmacol, 2005, 45(5): 555-63. [PubMed 15831779]

  • Nutescu EA, Shapiro NL, and Chevalier A, “New Anticoagulant Agents: Direct Thrombin Inhibitors,” Cardiol Clin, 2008, 26(2): 169-87. [PubMed 18406993]